Literature DB >> 23751870

Full-length human chromogranin-A cardioactivity: myocardial, coronary, and stimulus-induced processing evidence in normotensive and hypertensive male rat hearts.

Teresa Pasqua1, Angelo Corti, Stefano Gentile, Lorena Pochini, Mimma Bianco, Marie-Hélène Metz-Boutigue, Maria Carmela Cerra, Bruno Tota, Tommaso Angelone.   

Abstract

Plasma chromogranin-A (CgA) concentrations correlate with severe cardiovascular diseases, whereas CgA-derived vasostatin-I and catestatin elicit cardiosuppression via an antiadrenergic/nitric oxide-cGMP mediated mechanism. Whether these phenomena are related is unknown. We here investigated whether and to what extent full-length CgA directly influences heart performance and may be subjected to stimulus-elicited intracardiac processing. Using normotensive and hypertensive rats, we evaluated the following: 1) direct myocardial and coronary effects of full-length CgA; 2) the signal-transduction pathway involved in its action mechanism; and 3) CgA intracardiac processing after β-adrenergic [isoproterenol (Iso)]- and endothelin-1(ET-1)-dependent stimulation. The study was performed by using a Langendorff perfusion apparatus, Western blotting, affinity chromatography, and ELISA. We found that CgA (1-4 nM) dilated coronaries and induced negative inotropism and lusitropism, which disappeared at higher concentrations (10-16 nM). In spontaneously hypertensive rats (SHRs), negative inotropism and lusitropism were more potent than in young normotensive rats. We found that perfusion itself, Iso-, and endothelin-1 stimulation induced intracardiac CgA processing in low-molecular-weight fragments in young, Wistar Kyoto, and SHR rats. In young normotensive and adult hypertensive rats, CgA increased endothelial nitric oxide synthase phosphorylation and cGMP levels. Analysis of the perfusate from both Wistar rats and SHRs of untreated and treated (Iso) hearts revealed CgA absence. In conclusion, in normotensive and hypertensive rats, we evidenced the following: 1) full-length CgA directly affects myocardial and coronary function by AkT/nitric oxide synthase/nitric oxide/cGMP/protein kinase G pathway; and 2) the heart generates intracardiac CgA fragments in response to hemodynamic and excitatory challenges. For the first time at the cardiovascular level, our data provide a conceptual link between systemic and intracardiac actions of full-length CgA and its fragments, expanding the knowledge on the sympathochromaffin/CgA axis under normal and physiopathological conditions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23751870     DOI: 10.1210/en.2012-2210

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  16 in total

1.  Muscle injury, impaired muscle function and insulin resistance in Chromogranin A-knockout mice.

Authors:  Kechun Tang; Teresa Pasqua; Angshuman Biswas; Sumana Mahata; Jennifer Tang; Alisa Tang; Gautam K Bandyopadhyay; Amiya P Sinha-Hikim; Nai-Wen Chi; Nicholas J G Webster; Angelo Corti; Sushil K Mahata
Journal:  J Endocrinol       Date:  2016-10-31       Impact factor: 4.286

Review 2.  Chromogranins: from discovery to current times.

Authors:  Karen B Helle; Marie-Helene Metz-Boutigue; Maria Carmela Cerra; Tommaso Angelone
Journal:  Pflugers Arch       Date:  2017-09-05       Impact factor: 3.657

Review 3.  Chromogranin A: a paradoxical player in angiogenesis and vascular biology.

Authors:  Karen B Helle; Angelo Corti
Journal:  Cell Mol Life Sci       Date:  2014-10-09       Impact factor: 9.261

4.  [Changes in serum chromogranin A and urotensin II levels in children with chronic heart failure].

Authors:  Yao-Yao Cheng; Jin-Dou An; Song Feng; Wei Ge
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-03

5.  pGlu-serpinin protects the normotensive and hypertensive heart from ischemic injury.

Authors:  T Pasqua; B Tota; C Penna; A Corti; M C Cerra; P Loh Y; T Angelone
Journal:  J Endocrinol       Date:  2015-09-23       Impact factor: 4.286

6.  Cardiac electrical activity in a genomically "humanized" chromogranin a monogenic mouse model with hyperadrenergic hypertension.

Authors:  Nagendu B Dev; Saiful A Mir; Jiaur R Gayen; Jawed A Siddiqui; Maja Mustapic; Sucheta M Vaingankar
Journal:  J Cardiovasc Transl Res       Date:  2014-05-13       Impact factor: 4.132

Review 7.  Glycosylated Chromogranin A: Potential Role in the Pathogenesis of Heart Failure.

Authors:  Anett H Ottesen; Geir Christensen; Torbjørn Omland; Helge Røsjø
Journal:  Curr Heart Fail Rep       Date:  2017-12

Review 8.  Circulating chromogranin A and its fragments as diagnostic and prognostic disease markers.

Authors:  Angelo Corti; Fabrizio Marcucci; Tiziana Bachetti
Journal:  Pflugers Arch       Date:  2017-10-10       Impact factor: 3.657

9.  Cardiac and hepatic role of r-AtHSP70: basal effects and protection against ischemic and sepsis conditions.

Authors:  Teresa Pasqua; Elisabetta Filice; Rosa Mazza; Anna Maria Quintieri; Maria Carmela Cerra; Rina Iannacone; Donato Melfi; Cesare Indiveri; Alfonsina Gattuso; Tommaso Angelone
Journal:  J Cell Mol Med       Date:  2015-04-23       Impact factor: 5.310

Review 10.  The Emerging Roles of Chromogranins and Derived Polypeptides in Atherosclerosis, Diabetes, and Coronary Heart Disease.

Authors:  Takuya Watanabe
Journal:  Int J Mol Sci       Date:  2021-06-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.